← Back to Clinical Trials
Recruiting NCT07109739

NCT07109739 Dose-Response Effects of Inspiratory Muscle Strength Training on Blood Pressure and Vascular Function

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07109739
Status Recruiting
Phase
Sponsor University of Minnesota
Condition Systolic Hypertension
Study Type INTERVENTIONAL
Enrollment 144 participants
Start Date 2025-10-24
Primary Completion 2027-03-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
POWERbreathe K5

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 144 participants in total. It began in 2025-10-24 with a primary completion date of 2027-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will assess the dose-response effects of Inspiratory Muscle Strength Training (IMST) in adults with above-normal systolic blood pressure over a 6-week period.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Resting SBP ≥120 mmHg as measured during screening 1 \& 2 * Free from serious CV or metabolic diseases as identified by self-report and blood chemistry analysis. * No contraindications to IMST (recent abdominal surgery, ruptured eardrum, asthma with very low symptom perception, fractured ribs, or pneumothorax) * Language: English-speaking, with ability to comprehend study materials and instructions. * Pre-visit Compliance: Willing to comply with pre-visit instructions (avoiding food and caffeine ≥ 3 hours, vigorous exercise, alcohol, and non-prescribed medications ≥ 24 hours) prior to each measurement visit. * Lifestyle: Non-smokers (defined as self-report of not smoking cigarettes or vaping over the past year). Exclusion Criteria: * Self-report of history of cardiovascular disease, or conditions affecting the ear (e.g., ruptured eardrum). * Recent abdominal surgery or presence of an abdominal hernia. * Asthma with very low symptom perception, frequent severe exacerbations, or abnormally low perception of dyspnea. * Ruptured eardrum or any other condition of the ear. * Markedly elevated left ventricular end-diastolic volume and pressure. * Current respiratory conditions such as a cold, sinusitis, or respiratory tract infection (participants may be included once they recover from the respiratory condition). * Female-Specific: Pregnant or planning to become pregnant during the study period. * Compliance: Unable or unwilling to comply with pre-visit restrictions (e.g., avoiding caffeine, alcohol, and exercise within specified hours before visits).

Contact & Investigator

Central Contact

Hannah Westerberg

✉ lewi1241@umn.edu

📞 612-624-1588

Principal Investigator

Daniel Craighead, PhD

PRINCIPAL INVESTIGATOR

University of Minnesota

Frequently Asked Questions

Who can join the NCT07109739 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Systolic Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07109739 currently recruiting?

Yes, NCT07109739 is actively recruiting participants. Contact the research team at lewi1241@umn.edu for enrollment information.

Where is the NCT07109739 trial being conducted?

This trial is being conducted at Minneapolis, United States.

Who is sponsoring the NCT07109739 clinical trial?

NCT07109739 is sponsored by University of Minnesota. The principal investigator is Daniel Craighead, PhD at University of Minnesota. The trial plans to enroll 144 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology